A5070162381- Viral Infections and Outbreaks Research
- Liver Disease Diagnosis and Treatment
- Viral Infections and Vectors
- HIV Research and Treatment
- Immunotherapy and Immune Responses
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Pancreatitis Pathology and Treatment
- Diabetes Treatment and Management
- interferon and immune responses
- Herpesvirus Infections and Treatments
- Pharmacology and Obesity Treatment
- COVID-19 Clinical Research Studies
- Transgenic Plants and Applications
- Lipid metabolism and disorders
- Vector-Borne Animal Diseases
- Inflammasome and immune disorders
- Hepatitis B Virus Studies
- Respiratory viral infections research
- Bacillus and Francisella bacterial research
- Viral gastroenteritis research and epidemiology
- Virus-based gene therapy research
- Cytomegalovirus and herpesvirus research
- vaccines and immunoinformatics approaches
- Pancreatic function and diabetes
Altimmune (United States)
2021-2024
United States Army Medical Research Institute of Infectious Diseases
2017-2023
Altimmune (United Kingdom)
2022
University of Massachusetts Chan Medical School
2012-2015
BioScience Laboratories (United States)
2007-2010
Advanced Bioscience Laboratories (United States)
2007-2010
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent spread of severe acute respiratory syndrome 2 (SARS-CoV-2). Intranasal is an attractive strategy COVID-19 as nasal mucosa represents first-line barrier SARS-CoV-2 entry. current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose our candidate adenovirus type 5-vectored vaccine...
Background & AimsThis was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in subjects with metabolic dysfunction-associated steatotic disease (MASLD).MethodsSubjects BMI ≥28.0 kg/m2 and LFC ≥10% by magnetic resonance imaging-proton density fraction were randomized 1:1:1:1 pemvidutide at 1.2 mg, 1.8 or 2.4 placebo administered subcutaneously once weekly for 12...
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne capable of causing severe disease in humans. There are currently no licensed vaccines to prevent CCHFV-associated disease. We developed DNA vaccine expressing the M-segment glycoprotein precursor gene CCHFV and assessed its immunogenicity protective efficacy two lethal mouse models disease: type I interferon receptor knockout (IFNAR-/-) mice; novel transiently immune suppressed (IS) model. Vaccination mice by muscle...
It has been known since the discovery of DNA vaccines >20 y ago that can function as adjuvants. Our recent study reported involvement Aim2 sensor in eliciting Ag-specific Ab responses. findings indicated presence previously unrecognized innate immune response pathways addition to TLR9 pathway, which is mainly activated by CpG motifs vaccines. data further demonstrated requirement type I IFN vaccine-induced responses via but exact downstream molecular mechanism was not characterized. In...
Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne that causes severe disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested DNA vaccine expressing M-segment glycoprotein precursor gene of laboratory CCHFV strain IbAr 10200 (CCHFV-M ). CCHFV-M provided >60% protection against homologous CCHFV-IbAr challenge mice. Here, report increasing dose provides complete from mice, significant (80%) with...
Abstract Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in majority non-alcoholic steatohepatitis (NASH) patients, suggesting modulators may be effective controlling disease. The pharmacodynamics ALT-801, a GLP-1/glucagon receptor dual agonist optimized for NASH loss, were compared to semaglutide (GLP-1 agonist) elafibranor (peroxisome proliferator-activated receptor, PPAR-α/δ, biopsy-confirmed, diet-induced obese (DIO) mouse model (DIO-NASH). Male C57BL/6J...
Crimean-Congo hemorrhagic fever (CCHF) is a World Health Organization prioritized disease because its broad distribution and severity of make it global health threat. Despite advancements in preclinical vaccine development for CCHF virus (CCHFV), including multiple platforms targeting antigens, clear definition the adaptive immune correlates protection lacking. Levels neutralizing antibodies vaccinated animal models do not necessarily correlate with protection, suggesting that cellular...
Recent human study data have re-established the value of DNA vaccines, especially in priming high-level Ag-specific Ab responses, but also raised questions about mechanisms responsible for such effects. Whereas previous reports shown involvement downstream signaling molecules innate immune system, current investigated role absent melanoma 2 (Aim2) as a sensor vaccines. The Aim2 inflammasome directs maturation proinflammatory cytokines IL-1β and IL-18 an inflammatory form cell death called...
Introduction & Objective: Pemvidutide is a GLP-1/glucagon dual receptor agonist in development for treatment of obesity. Methods: MOMENTUM was Phase 2, randomized, placebo-controlled trial subjects with overweight (BMI 27.0-29.9 kg/m2) and at least one obesity-related comorbidity or obesity >30.0 randomized 1:1:1:1 to pemvidutide (1.2, 1.8, 2.4 mg) placebo administered subcutaneously weekly 48 weeks. Results: A total 391 mean age, body weight, BMI 50 yrs, 105 kg, 37 kg/m2 were...
DNA vaccines expressing codon-optimized Venezuelan equine encephalitis virus (VEEV) and Ebola (EBOV) glycoprotein genes provide protective immunity to mice nonhuman primates when delivered by intramuscular (IM) electroporation (EP). To achieve equivalent efficacy in the absence of EP, we evaluated VEEV EBOV constructed using minimalized Nanoplasmid expression vectors that are smaller than conventional plasmids used for vaccination. These may also be designed co-express type I interferon...
Immunoinformatics tools were used to predict human leukocyte antigen (HLA) class II-restricted T cell epitopes within the envelope glycoproteins and nucleocapsid proteins of Ebola virus (EBOV) Sudan (SUDV) structural Venezuelan equine encephalitis (VEEV). Selected tested for binding soluble HLA molecules representing 5 II alleles (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1501). All but one 25 peptides bound at least DRB1 alleles, 4 moderately or weakly all alleles. Additional...
Abstract We have previously shown that DNA vaccines expressing codon optimized alphavirus envelope glycoprotein genes protect both mice and nonhuman primates from viral challenge when delivered by particle-mediated epidermal delivery (PMED) or intramuscular (IM) electroporation (EP). Another technology with fewer logistical drawbacks is disposable syringe jet injection (DSJI) devices developed PharmaJet, Inc. These needle-free systems are spring-powered capable of delivering either IM into...
The coronavirus disease 2019 (COVID-19) pandemic has illustrated the critical need for effective prophylactic vaccination to prevent spread of severe acute respiratory syndrome 2 (SARS-CoV-2). Intranasal is an attractive approach preventing COVID-19 as nasal mucosa site initial SARS-CoV-2 entry and viral replication prior aspiration into lungs. We previously demonstrated that a single intranasal administration candidate adenovirus type 5-vectored vaccine encoding receptor-binding domain...
Abstract Background Differential pathogenicity has been observed in cynomolgus and rhesus macaques following primate lentivirus infection. However, little is known about the comparative susceptibility of pig‐tailed to infection diseases. Methods We compared vivo infectivity a CCR5‐tropic SHIV SF162 P4 after intravenous, intravaginal or intrarectal inoculation macaques. Plasma viral load, peripheral blood CD4 + T cell counts clinical signs were monitored. Results Both are similarly...
In previous studies, we showed that deoxyribonucleic acid (DNA) vaccines expressing codon-optimized filovirus envelope glycoprotein genes protect mice and nonhuman primates from viral challenge when delivered by intramuscular (IM) electroporation (EP). To determine whether could achieve equivalent immunogenicity protective efficacy a simplified delivery method, generated DNA vaccine plasmids genetic adjuvants to potentiate immune responses. We tested the Th1-inducing cytokine interleukin-12...